Targeted Oncology Staff

Lyudmila Bazhenova, MD, led a peer discussion about the frontline treatment options for a middle-aged male patient with ALK-positive non–small cell lung cancer.

A selection of therapies exist for patients with oncogene-driven lung cancer. Ticiana Leal, MD, discussed these options with a group of peers during a Targeted Oncology Case Based Peer Perspectives event.

During a Targeted Oncology Case Based Peer Perspective event, John V. Heymach, MD, PhD, discussed the testing methods for non–small cell lung cancer with MET exon 14 skipping mutations. The discussion was based on the case of a 48-year-old woman.

During a Targeted Oncology Case Based Peer Perspective event, Shilpa Gupta, MD, discussed the case of a 62-year-old man with bladder cancer.

During a Targeted Oncology Case Based Peer Perspectives event, Danielle Brander, MD, assistant professor of Medicine at Duke Cancer Institute in Durham, NC, discussed options for treating a 53-year-old female patients with chronic lymphocytic leukemia.

During a Targeted Oncology Case Based Peer Perspectives event, Bradley G. Somer, MD, discussed the case of a 30-year-old patients with bladder cancer.

During a Targeted Oncology Case Based Peer Perspective event, Jarushka Naidoo, MBBCh, discussed a case of a 63-year-old patients with non–small cell lung cancer.

During a Targeted Oncology Case Based Peer Perspectives event, Neeraj Agarwal, MD, discussed the case of a 57-year-old male patient with nonmetastatic castration resistant prostate cancer.

During a Targeted Oncology Case Based Peer Perspectives event, Thomas Hutson, DO, PharmD, discussed the case of a 66-year old woman with bladder cancer that presented post chemotherapy.

During Case Based Peer Perspectives event, Damian Laber, MD, discussed the case of a 53-year-old male patient with stage IV colorectal cancer.

During a Targeted Oncology Case Based Peer Perspectives event, Konstantinos Arnaoutakis, MD, discussed the case of a 63-year-old patient with non–small cell lung cancer.

During a Targeted Oncology Case Based Peer Perspectives event, Sandy Ting Liu, MD, discussed the case of a62-year-old male patient with bladder cancer.

During a Targeted Oncology Case Based Peer Perspective event, Barbara Pro, MD, discussed the case of a 60-year-old male patient with peripheral T-cell lymphoma.

During a Targeted Oncology Case Based Peer Perspective event, Alex Mejia-Garcia, MD, discussed the case of a 51-year-old male patient with stage II multiple myeloma.

Cyrus M. Khan, MD, discussed the case of a 61-year-old patient with bone marrow biopsy confirmed chronic lymphocytic leukemia during a Targeted Oncology Case Based Peer Perspectives event.

Haris Ali, MD, discussed the case of a 48-year-old patient with acute graft-versus-host disease.

Nilanjan Ghosh, MD, PhD, discussed the case of a 22-year-old patients with advanced Hodgkin lymphoma.

In an interview with Targeted Oncology, Peter Martin, MD, discusses the current mantle cell lymphoma treatment landscape and the future of the field.

During a Targeted Oncology Case Based Peer Perspective event, Jose Sandoval Sus, MD, discussed the guideline-recommended treatment options for a 71-year-old patient with chronic lymphocytic leukemia.

During a Case Based Peer Perspectives event Brian T. Hill, MD, PhD, discussed the case of a 53-year-old patients with chronic lymphocytic leukemia.

Alicia K. Morgans, MD, MPH, discussed the case of a 75-year-old male with metastatic castration-resistant prostate cancer.

Nathan A. Pennell, MD, PhD, discussed the case of 66-year-old patient with EGFR-mutant non–small cell lung cancer, during a virtual Case Based Peer Perspectives event.

Leslie M. Randall, MD, discussed the case of a 49-year-old African American patients with BRCA-mutated ovarian cancer.

Edward Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute in Charlotte, NC, discussed the use of atezolizumab and durvalumab as treatment of a 73-year-old female patient with extensive-stage small cell lung cancer during a virtual Case Based Peer Perspective event.

Alex Spira, MD, PhD, director, Virginia Cancer Specialists, Phase I Trial Program, Fairfax, VA, discussed the use of durvalumab as treatment of a 63-year-old male with unresectable stage III non–small cell lung cancer.

Ronald D. Alvarez, MD, MBA, weighs the pros and cons of adding bevacizumab to olaparib as treatment of a 69-year-old male patients with BRCA-mutant ovarian cancer.

Treatment options for a 69-year-old patient with poorly differentiated, infiltrative, cutaneous squamous cell carcinoma was discussed by Meredith McKean, MD, MPH and a group of physicians.

During a virtual Case Based Peer Perspective series, Zofia Piotrowska, MD, discussed the case of a 66-year-old man with non–small cell lung cancer and a genetic mutation.

The case of a 49-year-old African American woman with ovarian cancer was discussed during a virtual Case Based Peer Perspective event led by Matthew L. Anderson, MD, PhD.